In order to prevent spam,
this email address cannot be copied.
Schizophrenia Research Forum: Researcher Profile - Galila Agam
Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Researcher Profile - Galila Agam

First Name:Galila
Last Name:Agam
Advanced Degrees:PhD
Affiliation:Ben Gurion Univeristy of the Negev
Department:Psychiatry Research Unit & Clinical Biochemistry
Email Address:
(view policy) 
Member reports no financial or other potential conflicts of interest. [Last Modified: 1 December 2005]
Clinical Interests:
Bipolar disorder , Schizophrenia, Neurodevelopmental disorders (e.g., 22q11 deletion syndromes), Autism spectrum disorders (pervasive developmental disorders)
Research Focus:
Animal models, Molecular and Cell biology, Chemistry/pharmacology, Neurodevelopment, Neuropathology, DNA microrrays, Neurotransmission, Pharmacology, Protein structure/chemistry, Signal transduction, Glutamatergic transmission
Work Sector(s):
Web Sites:
Reasearcher Bio
1968: B.Sc., Chemistry, Biochemistry, Hebrew
University, Jerusalem
1970: M.Sc., Medical Sciences/Biochemistry -
with distinction, Hebrew University and
Hebrew University Medical School,
Jerusalem. Dept. of Clinical
Biochemistry, Hadassah Medical School,
1970-1980: Senior Research Assistant, in several
research labs in medical centers in
1980-1984:Instructor, Department of Biology, Ben-
Gurion University, Beer Sheva.
1984: Ph.D., Summa Cum Laude, Dept. of Life
Sciences, Ben Gurion University,
1989: Lecturer in Clinical Biochemistry,
Faculty of Health Sciences, Ben Gurion
University, Beersheva
1989-1997: Director, Laboratory of Biochemistry,
Soroka Medical Center, Beersheva
1993: Senior lecturer in Clinical
Biochemistry, Faculty of Health
Sciences, Ben-Gurion University,
1999 -: Associate Professor of Biochemistry in
Psychiatry, Ben- Gurion University,
Top Papers

Agam G, Livne A, 1989: Inositol-1-phosphatase of human erythrocytes is inhibited by therapeutic Li+ concentrations. Pyschiat. Res. 27:217-224.

Levine J, Rapaport A, Lev L, Bersudsky Y, Kofman O, Belmaker RH, Shapiro J, Agam G, 1993: Inositol treatment raises CSF inositol levels. Brain Res 627:168-170.

Agam G, Shapiro Y, Bersudsky Y, Kofman O, Belmaker RH, 1994: High-dose peripheral inositol raises brain inositol levels and reverses behavioral effects of inositol depletion by lithium. Pharmacol. Biochem. Behav. 49:341-343.

Shimon H, Agam G, Belmaker RH, Hyde TM, Kleinman JE., 1997: Reduced inositol levels in frontal cortex of post-mortem brain from bipolar patients and suicides. Am. J. Psychiat. 154: 1148-1150.

Shamir A, Ebstein RP, Nemanov L, Belmaker RH, Agam G., 1998: Inositol monophosphatase in immortalized lymphoblastoid cell lines indicates susceptibility to bipolar disorder and response to lithium therapy. Molec. Psychiatry 3:481-482.

Kozlovsky N, Belmaker RH, Agam G, 2000: Decreased GSK-3 immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am. J. Psychiatry. 157: 831-833.

Harwood AJ, Agam G., 2003: The search for a common mechanism of mood stabilizers. Biochemical Pharmacology, 66:179-89.

Ju S, Shaltiel G, Shamir A, Agam G, Greenberg ML., 2004: Human 1D-myo-inositol 3-phosphate synthase is functional in yeast. J Biol Chem. 279:21759-21765.

Shaltiel G, Shamir A, Shapiro J, Ding D, Dalton E, Bialer M, Harwood JA, Belmaker RH, Greenberg LM, Agam G. (2004): Valproate Decreases Inositol Biosynthesis. Biol Psychiatry 56:868-874.

Shaltiel G, Shamir A, Levy I, Bersudsky Y, Agam G. Lymphocyte G-protein receptor kinase (GRK)3 mRNA levels in bipolar disorder. Int J Neuropsychpharmacol, In press.

What are the top three papers (not yours) you have read recently?

Harrison PJ, Weinberger DR., Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005 Jan;10(1):40-68;

Abelson JF, Kwan KY, O'Roak BJ, Baek DY, Stillman AA, Morgan TM, Mathews CA, Pauls DL, Rasin MR, Gunel M, Davis NR, Ercan-Sencicek AG, Guez DH, Spertus JA, Leckman JF, Dure LS 4th, Kurlan R, Singer HS, Gilbert DL, Farhi A, Louvi A, Lifton RP, Sestan N, State MW. Sequence variants in SLITRK1 are associated with Tourette's syndrome.
Science. 2005 Oct 14;310(5746):317-20.

Lin CH, Hansen S, Wang Z, Storm DR, Tapscott SJ, Olson JM. The dosage of the neuroD2 transcription factor regulates amygdala development and emotional learning. Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14877-82. Epub 2005 Oct 3.

If resources were not limited, what research projects would you pursue?
Comparison cluster analysis of differently expressed genes in postmortem brain of tens of patients vs. brain from several animal models of schizophrenia, to decipher genes associated with inheritance of the disorder vs. genes involved in its environmental factors and epi-genetics.
What is your leading hypothesis?
Aberrant neurodevelopment and dopamine and NMDA neurotransmision
What piece of missing evidence would help prove it?
Do mRNA or protein levels of the major genes found aberrant in patients' postmortem brain show the same deviation in the animal models of the disease.

Treatment strategies to elevate in-vivo D-serine levels.

Research Participants
Copyright © 2005- 2016 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright